ZEPBOUND 2.5mg/0.5ml (Tirzepatide Vials) 2.5mg/0.5ml

Tirzepatide, the active ingredient in Zepbound, works by activating both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual action enhances insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite, leading to weight loss and improved metabolic control.

The usual starting dose of Zepbound is 2.5mg once weekly, which may be increased gradually under the supervision of a healthcare provider. The maximum recommended dose is 15mg once weekly. The prescriber will determine the appropriate dose based on individual patient needs and response to treatment.

The safety of Zepbound during pregnancy or breastfeeding has not been established. It is important to consult with a healthcare provider before using Zepbound if you are pregnant, planning to become pregnant, or breastfeeding. The prescriber will weigh the potential benefits against the risks to determine the best course of action.

To order Zepbound from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. The team will ask you to confirm your trade or institutional credentials and will then provide pricing, availability, shipping (including cold-chain where relevant), and the necessary import paperwork.

Zepbound is unique in that it is a dual GIP/GLP-1 receptor agonist, which is different from other weight loss medications that may only target one of these receptors. This dual action can provide a more comprehensive approach to weight management. However, the choice of medication depends on individual patient needs and should be discussed with a healthcare provider.

Zepbound should be stored in the refrigerator between 36°F to 46°F (2°C to 8°C). It can be stored at room temperature up to 86°F (30°C) for up to 21 days. Once removed from the refrigerator, do not return it to the fridge. Never freeze Zepbound and always protect it from light by storing it in the original carton.

Zepbound is administered as a subcutaneous injection once weekly. It comes in pre-filled pens or vials, and the injection can be given at any time of the day. Patients or caregivers should be properly trained on how to administer the injection to ensure safety and effectiveness.

The most serious risks associated with Zepbound include tumors in the thyroid, including thyroid cancer, pancreatitis, hypoglycemia, gallbladder problems, kidney problems, and allergic reactions. Patients should be monitored for symptoms such as a lump or swelling in the neck, severe abdominal pain, signs of low blood sugar, and allergic reactions, and should report these to their healthcare provider immediately.

Zepbound should not be used by individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It should also not be used by those who have had a serious allergic reaction to tirzepatide or any of its ingredients. Patients should consult with their healthcare provider to determine if Zepbound is suitable for them.